on Vogenx, Inc. (NASDAQ:VOGX)
Vogenx Set to Join Key Russell Indexes
Vogenx, Inc., a clinical-stage biopharmaceutical company focused on treating serious metabolic and gastrointestinal diseases, is set to join the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes. This inclusion is part of FTSE Russell's December 2026 semi-annual reconstitution. The membership will be effective post-market close on December 11, 2026. This marks a pivotal moment for Vogenx, occurring just months after its IPO.
James Green, CEO of Vogenx, remarked that this development will enhance the company's visibility among institutional investors as it continues the Phase 2b EMERGE study of mizagliflozin for post-bariatric hypoglycemia, a condition currently lacking FDA-approved treatments.
The Russell US Indexes are vital benchmarks for investment managers. The December 2026 reconstitution is notable as it follows FTSE Russell's shift to a semi-annual update schedule. Vogenx's inclusion reflects the company's market cap and growth potential.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Vogenx, Inc. news